Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Overview
Date Founded

2008

Headquarters

ONE Copley Parkway, Suite 490, Morrisville, NC, 27560, USA

Type of Company

Public

Employees (Worldwide)

9

Industries

Hospitals & Patient Services
Pharmaceuticals
Biotechnology

Company Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company has a world-class scientific advisory team, including recognized global experts in pulmonary hypertension. The company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Contact Data
Trying to get in touch with decision makers at Tenax Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Executive Officer

President & Chief Financial Officer

Executive Vice President-Legal Affairs, General Counsel & Corporate Secretary

Chief Medical Officer

Executive Vice President of Commercial & Business Operations

Executive Vice President Regulatory Affairs

Director, Clinical Operations

Sales Director

Study Principal Investigator

Board of Directors

Chairman at Martin, Blanck & Associates

Chief Investment Officer at Armistice Capital LLC

Former President-Americas Region at EUSA Pharma, Inc.

Chief Executive Officer at Danish Silver A/S

Founder at Dermata Therapeutics LLC

Managing Director at Armistice Capital LLC

Paths to Tenax Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Tenax Therapeutics, Inc.
Recent Transactions
Details Hidden

Tenax Therapeutics, Inc. issued USD Common Stock

Details Hidden

Tenax Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Tenax Therapeutics, Inc., Life Newco, Inc. purchase Phyxius Pharma, Inc.

Transaction Advisors
Investment Advisor

Advised onTenax Therapeutics, Inc. raised money in a private placement transaction

Auditor

Advised onTenax Therapeutics, Inc. issued USD Common Stock

Escrow Agent

Advised onTenax Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onTenax Therapeutics, Inc. issued USD Common Stock

Professional

Advised onTenax Therapeutics, Inc. issued USD Common Stock

Managing Director & Partner

Advised onTenax Therapeutics, Inc., Life Newco, Inc. purchase Phyxius Pharma, Inc.

Advisors & Consultants
Advisor

Former Senior Analyst at Stern Investor Relations, Inc.

Key Stats and Financials As of 2019
Market Capitalization
$23.3M
Total Enterprise Value
$3.51M
Earnings Per Share
$-1.35
Revenue
$0
Net Profit
$-8.39M
EBITDA
$-8.45M
Total Debt
$172K
Total Equity
$3.77M
TEVNet Income
-0.42x
Debt TEV
0.05x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
-100%
Suppliers
Orion Oyj Pharmaceuticals | Espoo, Finland

Orion in brief Orion as a company Orion Group operational structure Best selling products Business environment Business Divisions Line functions Operational model Strategy Partnering / Licensing Corporate Governance General Meetings of Shareholders History Values Orion Events Calendar 2013 Home / Orion / Orion in brief / Orion as a company Print Orion as a company Orion Corporation develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Orion has been building well-being already for 95 years. Orion as a listed company Orion’s Shares A and B are quoted on the NASDAQ OMX Helsinki in the Large Cap group under the Healthcare sector heading. Trading in both of the company’s share classes commenced on 3 July 2006 under the trading codes ORNAV and ORNBV. Information on trading in the company’s shares has been available since this date. Clientele Orion’s clientele consists of healthcare service providers and professionals, such as doctors, pharmacies, hospitals, healthcare centers, clinics and laboratories. Pharmaceuticals business Pharmaceuticals account for about 95% of Orion’s net sales, of which a considerable part comes from proprietary patented pharmaceutical innovations. The core therapy areas in Orion’s product and research strategy are: central nervous system oncology and critical care respiratory medicines administered with the Easyhler device. Orion has also a large portfolio of generic, off-patent prescription medicines, hospital treatments and self-care products. These products are sold mainly in Finland, other Nordic countries, the new EU countries and Germany. In animal health, Orion has the leading market position in its home territory, the Nordic countries. The subsidiary Fermion produces active pharmaceutical ingredients for both Orion and other pharmaceutical companies. Diagnostics business Orion’s diagnostic tests are used widely around the world to help in diagnosing patients and to contribute to the follow-up of treatment. The emphasis in this product sector is on easy-to-use and rapid point-of-care tests. The leading brand is the QuikRead® CRP test for diagnosing infections.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tenax Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tenax Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Tenax Therapeutics, Inc..